Immune mechanisms of allergen-specific sublingual immunotherapy (Q34484071)

2 August 2017

1 reference

title

Immune mechanisms of allergen-specific sublingual immunotherapy (English)

1 reference

2 August 2017

1 reference

Moingeon P

1

1 reference

2 August 2017

Batard T

2

1 reference

2 August 2017

Fadel R

3

1 reference

2 August 2017

Frati F

4

1 reference

2 August 2017

Sieber J

5

1 reference

2 August 2017

Van Overtvelt L

6

1 reference

2 August 2017

publication date

1 February 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

61

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

151-165

1 reference

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

21 January 2018

Specific immunotherapy

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Noninjection routes for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual and oral immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Mechanisms of allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Mechanisms of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Vaccination with genetically engineered allergens prevents progression of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Renaissance of the blocking antibody concept in type I allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4 T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy decreases the number of mast cells in the skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

T cell activation, from atopy to asthma: more a paradox than a paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Increases in IL-12 messenger RNA cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Allergen immunotherapy decreases interleukin 4 production in CD4 T cells from allergic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4 CD25 interleukin-10 T cells expressing peripheral tissue trafficking markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

T regulatory cells in allergy and health: a question of allergen specificity and balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Interleukin-10, T regulatory cells and specific allergy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

A CD4 T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Regulatory T cells control the development of allergic disease and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

The regulatory T cell family: distinct subsets and their interrelations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

A role for TGF-beta in the generation and expansion of CD4 CD25 regulatory T cells from human peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Foxp3 programs the development and function of CD4 CD25 regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

In vitro generation of interleukin 10-producing regulatory CD4( ) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Activation of human CD4 cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Human CD25 regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4 T helper cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Allergy, parasites, and the hygiene hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Relation of CD4 CD25 regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Mechanism of IL-10-induced T cell inactivation in allergic inflammation and normal response to allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Allergen-specific T cells from birch-pollen-allergic patients and healthy controls differ in T helper 2 cytokine and in interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Asymptomatic atopy is associated with increased indoleamine 2,3-dioxygenase activity and interleukin-10 production during seasonal allergen exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Delivery of bioactive peptides and proteins across oral (buccal) mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Peptidase activity on the surface of the porcine buccal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

The effect of antigen dose on CD4 T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Generation and maintenance of memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

Induction of IL-10 CD4 CD25 T cells by grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1398-9995.2006.01002.X

10.1111/J.1398-9995.2006.01002.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference